Korean Gliptins Loom Amid Signs Of Shifts In India
This article was originally published in PharmAsia News
Executive Summary
A clutch of new dipeptidyl peptidase-4 (DPP-4) inhibitors including LG Life Sciences Ltd's gemigliptin and Dong-A ST Co. Ltd 's evogliptin have either just hit the Indian market or are on the horizon, amid what some industry watchers say are early signs of a volume shake-up in the highly competitive gliptins market.
You may also be interested in...
Indo-Korean Pharma Linkages: A New Emerging Asian Front?
Is there a new strategic Asian pharma partnership in the works? Early days perhaps but worth keeping an eye on the India-South Korea deal street.
Asia Deal Watch: China Grand, ETheRNA Create mRNA Vaccine JV
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Precious Cargo: DHL Gears To Deliver COVID-19 Vaccines
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
Need a specific report? 1000+ reports available
Buy Reports